HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Zappasodi et al. - Supplementary Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Zappasodi, R. Articles by Gianni, A. M. PubMed PubMed Citation Articles by Zappasodi, R. Articles by Gianni, A. M. Related Collections Related Article

The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells

¹ "C. Gandini" Medical Oncology, Bone Marrow Transplantation Unit
² "Human Tumor Immunobiology Unit, Fondazione IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
³ Chair of Medical Oncology, University of Milan, Milan, Italy
⁴ ’Stephen Chair, Arizona Arthritis Center, University of Arizona, Tucson, AZ, USA

Correspondence: Massimo Di Nicola, "Cristina Gandini" Bone Marrow Transplantation Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy. E-mail:massimo.dinicola{at}istitutotumori.mi.it

Background: Adoptive cell therapy with ex vivo expanded autologous antitumor cytotoxic T lymphocytes represents an important therapeutic option as an anticancer strategy. In order to identify a reliable method for producing adequate amounts of functional antitumor cytotoxic T lymphocytes with a potentially long in vivo lifespan, we tested the T-cell expansion efficiency of a new artificial antigen-presenting cell-based system.

Design and Methods: Our artificial antigen-presenting cells were generated with activating (anti-CD3), co-stimulating (anti-CD28) and adhesion (anti-LFA-1) biotinylated monoclonal antibodies preclusterted in microdomains held on a liposome scaffold by neutravidin rafts. The co-localization of T-cell ligands in microdomains and the targeting of an adhesion protein, increasing the efficiency of immunological synapse formation, represent the novelties of our system. The activity of our artificial antigen-presenting cells was compared with that of anti-CD3/-CD28 coated immunomagnetic microbeads and immobilized anti-CD3 monoclonal antibody (OKT3 clone), the only two commercially available artificial systems.

Results: Our artificial antigen-presenting cells expanded both polyclonal T cells and MART-1-specific CD8⁺ T cells in a more efficient manner than the other systems. Stimulation with artificial antigen-presenting cells allows for the generation of viable T cells displaying an immunophenotype consistent with in vivo potential for persistence, without increasing the frequency of regulatory T cells. The starting specificity of anti MART-1 CD8⁺ T cells was preserved after stimulation with artificial antigen-presenting cells and it was statistically greater when compared to the activity of the same cells expanded with the other systems. Finally, our artificial antigen-presenting cells proved to be suitable for large-scale application, minimizing the volume and the costs of T-cell expansion.

Conclusions: Our artificial antigen-presenting cells might represent an efficient tool to rapidly obtain a sufficient number of functional T cells for adoptive immunotherapy in patients with cancer.

Key words: cytotoxic T cells, T-cell activation, T-cell differentiation, co-stimulation, tumor immunity.

Related Article

Adoptive T-cell therapy for malignant disorders

Daniel J. Powell, Jr, Bruce L. Levine
Haematologica 2008 93: 1452-1456. [Full Text] [PDF]

This article has been cited by other articles:

				D. J. Powell Jr and B. L. Levine Adoptive T-cell therapy for malignant disorders Haematologica, October 1, 2008; 93(10): 1452 - 1456. [Full Text] [PDF]